Steven Tong
steventong.bsky.social
Steven Tong
@steventong.bsky.social
Infectious diseases, clinical trials, staphylococcus and streptococcus. Reader and runner. Go Hawks!
The 3rd and 4th commentaries on recent ID trials are up on the CLARITY website (we aim to publish in depth reviews of important ID stuies).

This time looking at the GAMECHANGER trial:
clarityinitiative.org/commentaries...

@erinmccreary.bsky.social with Ahmad Mourad

@gurujosh.bsky.social

#IDSky
How Do We Win? The GAME CHANGER Trial
Erin K. McCreary, PharmD (1), Ahmad Mourad, MD MHS (2, 3)
clarityinitiative.org
January 1, 2026 at 11:50 PM
Reposted by Steven Tong
The numbers are in.

This year's most popular JAMA content spans a range of topics, from coffee and #AFib to #osteoporosis to #SepticShock. What was your favorite article in 2025—and did other readers agree?

🔗 ja.ma/49dIcKr
December 28, 2025 at 4:00 PM
Reposted by Steven Tong
🆕🔥State of art review article by 🌟 s
@drtoddlee.bsky.social @steventong.bsky.social
Navigating the Challenges in Staphylococcus aureus Bloodstream Infection: A Practical Guide to Management #idsky #EMIMCC
www.sciencedirect.com/science/arti...
December 6, 2025 at 12:34 PM
New article about how to manage Staphylococcus aureus bacteremia. Led by Hadar Mudrik-Zohar. Includes @seanong.bsky.social @drtoddlee.bsky.social
#IDSky #SNAP_trial

www.sciencedirect.com/science/arti...
Navigating the Challenges in Staphylococcus aureus Bloodstream Infection: A Practical Guide to Management
www.sciencedirect.com
December 4, 2025 at 2:53 AM
A reflection on decades of work to improve skin health in remote Australian communities: www.nhmrc.gov.au/about-us/res...

@ashabowen.bsky.social @nhmrc.bsky.social @thedohertyinst.bsky.social
www.nhmrc.gov.au
December 4, 2025 at 2:51 AM
Reposted by Steven Tong
A group of ID clinical researchers passionate about clinical research and evidence appraisal has just launched the CLARITY initiative (clarityinitiative.org), which aims to improve the generation and interpretation of evidence in ID and Microbiology.
Clarity Initiative
Clinical Literature Appraisal and Research education in InfecTious diseases
clarityinitiative.org
November 30, 2025 at 11:40 PM
Reposted by Steven Tong
Reposted by Steven Tong
Our new paper in @cmijournal.bsky.social:

www.clinicalmicrobiologyandinfection.org/article/S119...

We use the BALANCE and CAMERA2 trials as case studies to illustrate the use of the different methods available for analysis of hierarchical composite endpoints.

#IDSky @steventong.bsky.social
Comparing different methods for analyzing hierarchical composite endpoints: two illustrative case studies with post-hoc analyses of the BALANCE and CAMERA2 randomized clinical trials.
Hierarchical composite endpoints (HCEs) are increasingly being used in infectious disease research. In this paper, we illustrate different methods for analyzing HCEs in post-hoc analyses of the BALANC...
www.clinicalmicrobiologyandinfection.org
November 30, 2025 at 11:30 PM
Reposted by Steven Tong
Fascinating: NEJM AI using AI for peer review. Combining human and AI reviews.
I've often wondered if this is a next step. I can imagine that there are already instances of AI written papers, reviewed by AI. (this is NOT the case here) ai.nejm.org/doi/full/10....
Accelerating Science with Human+AI Review
This issue of NEJM AI features the first two articles published through our accelerated human+AI review process. In this editorial, we describe the invitation-only “Fast Track” process used to revi...
ai.nejm.org
November 30, 2025 at 10:38 AM
Reposted by Steven Tong
Infectious disease guidelines now rely on RCTs over observational data. CLARITY launched for education & critique. 1st course Nov 2026; join to review trials! 📚🦠##idsky
The CLARITY initiative: <u>C</u>linical <u>L</u>iterature <u>A</u>ppraisal and <u>R</u>esearch education in <u>I</u>nfec<u>T</u>ious diseases and microbiolog<u>Y</u>
Over the past two decades, the generation and application of clinical evidence in the fields of clinical infectious diseases and microbiology have entered a new era: one in which clinical guidelines are increasingly informed by large, well designed randomised controlled trials rather than relying on observational evidence, in-vitro data or expert opinion. This change has been catalysed and informed by similar earlier developments in other areas of medicine, such as cardiovascular medicine and critical care medicine.We are hence now at a nodal point in our speciality, where our clinical decisions can be increasingly informed by high-level clinical evidence. This change goes hand in hand with the need for all those practicing in our fields to deepen their understanding of the design, conduct and particularly the interpretation of randomised controlled trials. Further, studies analysing observational datasets with advanced methods for causal inference are being used more broadly. Such studies and their methods require critical appraisal before conclusions are drawn. To help inform our clinical community we recently launched the CLARITY initiative: a non-profit academic collaboration of clinicians and researchers in the fields of infectious diseases and microbiology (www.clarityinitiative.org). The two main pillars of CLARITY are education and critical appraisal of the literature.We owe our critical care colleagues for the inspiration for CLARITY. In particular, we acknowledge Dr Rob Mac Sweeney and the team behind Critical Care Reviews (https://www.criticalcarereviews.com/), an incredible resource that, over the 15 years since its launch, has grown to be the premiere source of trusted reviews of the literature in critical care medicine, as well as hosting a highly popular conference.The education element of CLARITY will focus on clinical trials design and methodology; we plan to run courses on this aimed at trainees in our fields, as well as specialists who are not yet experienced in clinical trials. The first of these will take place in Europe in November 2026. With regards to critical appraisal of the literature, we will publish regular in-depth analyses and interpretations of important clinical trials, both on our website (https://www.clarityinitiative.org) and in CMI Communications. The first of these is published in this edition of CMI Communications [1].Who will write these commentaries? We are hoping that you, the clinical infectious diseases and microbiology community, will help with that! The CLARITY initiative is a group of volunteers – we invite all of you to join in these activities and grow our pool of regular reviewers. Commentaries are submitted via the CLARITY website and will be screened and reviewed by CLARITY faculty with a revised commentary then posted onto the CLARITY website for rapid dissemination. We will also ask the reviewers to submit this revised commentary to CMI Communications (in the ‘Commentary’ category - up to 1,400 words and 10 references) for formal peer review and consideration of publication (https://www.sciencedirect.com/journal/cmi-communications/publish/guide-for-authors). There will be no article processing charge.So, please keep an eye out for practice-changing clinical trials and high-quality observational studies that use robust causal inference methods in infectious diseases and microbiology, and consider writing a commentary: how was the trial designed and conducted – are there critical limitations? What did the results show, and more importantly what do these results mean to you, and for everyday practice? Some commentaries may focus on more methodological issues, and others on the clinical implications and context of the findings. All commentaries should start with a summary paragraph with the key findings of the paper, how you interpret them, and what you think their implications are for clinical practice.We look forward to working with you on this initiative. If you are interested in helping out with CLARITY, or simply want to know more, please get in touch with us on the below email addresses.FundingNoneProf Josh Davis – University of Newcastle, Newcastle, AustraliaJoshua.Davis@health.nsw.gov.auProf Steven Tong – University of Melbourne, Melbourne, AustraliaSteven.Tong@unimelb.edu.auConflict of interestNone
www.sciencedirect.com
November 30, 2025 at 6:30 AM
@seanong.bsky.social is giving his PhD oration today at 12.30pm AEDT. If you are free, you will learn heaps about clinical trials in infectious diseases. It's been an incredible PhD journey!

unimelb.zoom.us/j/8944229688...

@thedohertyinst.bsky.social
November 16, 2025 at 10:53 PM
Check this out! A Cultural Information Hub from the #SNAPTrial. Hopefully the collation of resources are useful for any research projects wanting to build cultural competence among research staff and teams.

@nhmrc.bsky.social @unimelb.bsky.social @thedohertyinst.bsky.social @thekidsau.bsky.social
We have launched the #SNAPTrial Cultural Information Hub.

Leadership in clinical trial training & cultural safety from our Australian Aboriginal Advisory Committee.

www.snaptrial.com.au/cultural-inf...

Inclusivity & equity in recruiting participants

@steventong.bsky.social
November 16, 2025 at 2:23 AM
@seanong.bsky.social takes to the next level analysis of the BALANCE trial (7 vs 14 days of antibiotics) and impact of protocol non-adherence (there was about 20% non-adherence to protocol durations).

Read his thread and read his paper!

@thelancetinfdis.bsky.social @thedohertyinst.bsky.social
Hot off the press at @thelancetinfdis.bsky.social: our paper diving into non-adherence in the BALANCE trial. We identify factors associated with protocol non-adherence, and evaluate the impact of potential bias on trial results.

authors.elsevier.com/a/1m5He5E-Uo...

@steventong.bsky.social #IDSky
authors.elsevier.com
November 12, 2025 at 1:30 AM
Want to come work on SNAP, BALANCE+, and STRAP? And change how we treat and manage bloodstream infections? See below. #IDSky
We are looking for candidates for a new fully-funded joint PhD position at the Universities of Toronto and Melbourne, working on RCTs in bloodstream infection (BALANCE+, SNAP, STRAP).

More info here: forms.gle/H9TXEMkwM1cb...

Please spread far and wide!
@steventong.bsky.social #IDSky
forms.gle
October 27, 2025 at 9:28 AM
Reposted by Steven Tong
We’re kicking off #Antimicrobials2026 with Symposium 1: Staphylococcus aureus, featuring two outstanding speakers.

💊 Prof @steventong.bsky.social
SNAP Update

🧬 Prof Anton Y. Peleg
Daptomycin and MRSA

Register now: www.antimicrobials.com.au
#MRSA #idsky #amssky #clinmicrosky
October 23, 2025 at 6:06 AM
Reposted by Steven Tong
🆕🔥🔥CloCeBa RCT
Cloxacillin versus cefazolin for MSSA Bacteraemia
Cefazolin has a non-inferior efficacy regarding mortality, microbiological or clinical endpoints and was associated with a lower rate of serious adverse events #IDSky
www.thelancet.com/journals/lan...
October 19, 2025 at 4:34 AM
International funding flows in infectious diseases clinical trials published in selected high-impact journals over a 10-year period

New paper in @cmijournal.bsky.social, led by @seanong.bsky.social.

See thread for details.

@thedohertyinst.bsky.social @unimelb.bsky.social #IDSky
Our new paper in @cmijournal.bsky.social led by the brilliant Hadrien Moffroid, a junior colleague in Melbourne. We examined international funding flows in ID RCTs published in selected high-impact journals over a 10-year period.

doi.org/10.1016/j.cm...
@steventong.bsky.social #IDSky
September 29, 2025 at 10:48 PM
Reposted by Steven Tong
Free access to our article on the inclusion of LMICs in platform trials of bloodstream infections. SNAP in Johannesburg. @steventong.bsky.social @gurujosh.bsky.social

authors.elsevier.com/a/1lVzy,RGPg...
authors.elsevier.com
July 29, 2025 at 6:18 AM
Reposted by Steven Tong
Glad to have the opportunity to collaborate with Spanish colleagues on this. We conducted a pooled Bayesian post-hoc analysis of the BACSARM and SAFO trials evaluating combination therapy with fosfomycin for SAB. The door may not be closed on adjunctive fosfomycin! Justifies need for more RCTs.
July 18, 2025 at 12:53 AM
The Staphylococcus aureus Network Adaptive Platform (SNAP) trial has been nominated for a Patient healthcare communication award!

Public voting is now open 👉 ccrew.accesscr.com.au/cpir-2025/pu...

Find out more about SNAP 🔗 www.snaptrial.com.au

Give us a vote!!

@thedohertyinst.bsky.social
SNAP Trial – Staphylococcus aureus Network Adaptive Platform Trial
SNAP aims to improve treatment outcomes for patients with Staphylococcus aureus bloodstream infections. This website provides information for participants, members of the public, and healthcare profes...
www.snaptrial.com.au
July 8, 2025 at 3:37 AM
Reposted by Steven Tong
Thrilled to share our new research led by Jane Davies @menziesresearch.bsky.social on First Nations people in the NT living with chronic hepatitis B. An important study that could inform better care:

doi.org/10.1186/s128...

#idsky #MedSky #HepSky #LiverSky
July 2, 2025 at 1:31 AM
Reposted by Steven Tong
Thankful for another opportunity to write this editorial with @steventong.bsky.social in @jama.com: jamanetwork.com/journals/jam...

We discuss this trial, which evaluated the impact of different recruitment letter formats on RCT enrolment: jamanetwork.com/journals/jam...
Trials Within Trials—Optimizing the Delivery of RCTs
In the latest issue of JAMA, Johansen and colleagues1 report the results of a trial that investigated the impact of digital recruitment letter formats on recruitment to a larger clinical trial, the DA...
jamanetwork.com
June 26, 2025 at 3:03 AM